Rani Therapeutics Holdings Stock Market Value
| RANI Stock | USD 1.36 0.01 0.74% |
| Symbol | Rani |
Rani Therapeutics Price To Book Ratio
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.77) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Rani Therapeutics 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to Rani Therapeutics' stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of Rani Therapeutics.
| 12/06/2025 |
| 01/05/2026 |
If you would invest 0.00 in Rani Therapeutics on December 6, 2025 and sell it all today you would earn a total of 0.00 from holding Rani Therapeutics Holdings or generate 0.0% return on investment in Rani Therapeutics over 30 days. Rani Therapeutics is related to or competes with Innate Pharma, Milestone Pharmaceuticals, Cardiff Oncology, Cybin, Corbus Pharmaceuticals, Sangamo Therapeutics, and Tonix Pharmaceuticals. Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered ... More
Rani Therapeutics Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure Rani Therapeutics' stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess Rani Therapeutics Holdings upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 7.02 | |||
| Information Ratio | 0.1176 | |||
| Maximum Drawdown | 264.02 | |||
| Value At Risk | (12.65) | |||
| Potential Upside | 26.67 |
Rani Therapeutics Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for Rani Therapeutics' investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as Rani Therapeutics' standard deviation. In reality, there are many statistical measures that can use Rani Therapeutics historical prices to predict the future Rani Therapeutics' volatility.| Risk Adjusted Performance | 0.0946 | |||
| Jensen Alpha | 3.45 | |||
| Total Risk Alpha | 1.31 | |||
| Sortino Ratio | 0.5425 | |||
| Treynor Ratio | 0.5187 |
Rani Therapeutics Backtested Returns
Rani Therapeutics is out of control given 3 months investment horizon. Rani Therapeutics maintains Sharpe Ratio (i.e., Efficiency) of 0.12, which implies the firm had a 0.12 % return per unit of risk over the last 3 months. We were able to interpolate thirty different technical indicators, which can help you to evaluate if expected returns of 4.13% are justified by taking the suggested risk. Use Rani Therapeutics Coefficient Of Variation of 836.21, risk adjusted performance of 0.0946, and Semi Deviation of 5.56 to evaluate company specific risk that cannot be diversified away. Rani Therapeutics holds a performance score of 9 on a scale of zero to a hundred. The company holds a Beta of 7.45, which implies a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Rani Therapeutics will likely underperform. Use Rani Therapeutics maximum drawdown, accumulation distribution, relative strength index, as well as the relationship between the semi variance and day typical price , to analyze future returns on Rani Therapeutics.
Auto-correlation | 0.72 |
Good predictability
Rani Therapeutics Holdings has good predictability. Overlapping area represents the amount of predictability between Rani Therapeutics time series from 6th of December 2025 to 21st of December 2025 and 21st of December 2025 to 5th of January 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of Rani Therapeutics price movement. The serial correlation of 0.72 indicates that around 72.0% of current Rani Therapeutics price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.72 | |
| Spearman Rank Test | 0.62 | |
| Residual Average | 0.0 | |
| Price Variance | 0.0 |
Rani Therapeutics lagged returns against current returns
Autocorrelation, which is Rani Therapeutics stock's lagged correlation, explains the relationship between observations of its time series of returns over different periods of time. The observations are said to be independent if autocorrelation is zero. Autocorrelation is calculated as a function of mean and variance and can have practical application in predicting Rani Therapeutics' stock expected returns. We can calculate the autocorrelation of Rani Therapeutics returns to help us make a trade decision. For example, suppose you find that Rani Therapeutics has exhibited high autocorrelation historically, and you observe that the stock is moving up for the past few days. In that case, you can expect the price movement to match the lagging time series.
Current and Lagged Values |
| Timeline |
Rani Therapeutics regressed lagged prices vs. current prices
Serial correlation can be approximated by using the Durbin-Watson (DW) test. The correlation can be either positive or negative. If Rani Therapeutics stock is displaying a positive serial correlation, investors will expect a positive pattern to continue. However, if Rani Therapeutics stock is observed to have a negative serial correlation, investors will generally project negative sentiment on having a locked-in long position in Rani Therapeutics stock over time.
Current vs Lagged Prices |
| Timeline |
Rani Therapeutics Lagged Returns
When evaluating Rani Therapeutics' market value, investors can use the concept of autocorrelation to see how much of an impact past prices of Rani Therapeutics stock have on its future price. Rani Therapeutics autocorrelation represents the degree of similarity between a given time horizon and a lagged version of the same horizon over the previous time interval. In other words, Rani Therapeutics autocorrelation shows the relationship between Rani Therapeutics stock current value and its past values and can show if there is a momentum factor associated with investing in Rani Therapeutics Holdings.
Regressed Prices |
| Timeline |
Currently Active Assets on Macroaxis
When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:Check out Rani Therapeutics Correlation, Rani Therapeutics Volatility and Rani Therapeutics Alpha and Beta module to complement your research on Rani Therapeutics. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Rani Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.